MetaCap

GH Research (GHRS) vs Mineralys Therapeutics (MLYS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

GH Research (GHRS) has outperformed Mineralys Therapeutics (MLYS) over the past year, gaining 25.1% versus a loss of 67.4%. Mineralys Therapeutics is the larger company by market cap ($1.21 billion vs $1.20 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

GHRS+25.08%MLYS-67.38%
+128%+26%-77%
Nov 21, 20251 yearNov 20, 2026
GHRS+74.78%MLYS-25.92%
+215%+68%-79%
Feb 6, 20235 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

GHRS versus MLYS key metrics
MetricGHRSMLYS
Share price$17.53$13.66
Market cap$1.20B$1.21B
1-day change-5.55%-3.53%
YTD return+38.03%-62.36%
1-year return+25.08%-67.38%
5-year return-21.00%—
EPS (TTM)$-0.94$-4.30
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-48.26M$-154.65M
52-week high$31.44$44.13
52-week low$12.04$13.57
Distance from 52-week high-44.24%-69.05%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+144.67%+218.89%
Average volume294.69K1.55M
Shares outstanding68.68M88.56M
Employees7376
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • GHRS has outperformed MLYS by 92.5 percentage points over the past year.

About GH Research

GHRS stock →

GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression.

Health Care · Biotechnology: Pharmaceutical Preparations · 73 employees

About Mineralys Therapeutics

MLYS stock →

Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea.

Health Care · Biotechnology: Pharmaceutical Preparations · 76 employees

GHRS vs MLYS FAQ

Which is bigger, GH Research or Mineralys Therapeutics?

Mineralys Therapeutics (MLYS) is larger, with a market capitalization of $1.21B compared with $1.20B for GH Research (GHRS).

Which stock has performed better over the past year, GHRS or MLYS?

GHRS returned +25.08% over the past 12 months, compared with -67.38% for MLYS (price return, excluding dividends). Past performance does not predict future results.

Are GH Research and Mineralys Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons